Association of Radiochemotherapy to Immunotherapy in unresectable locally advanced Oesophageal carciNoma—randomized phase 2 trial ARION UCGI 33/PRODIGE 67: the study protocol

BACKGROUND: In case of locally advanced and/or non-metastatic unresectable esophageal cancer, definitive chemoradiotherapy (CRT) delivering 50 Gy in 25 daily fractions in combination with platinum-based regimen remains the standard of care resulting in a 2-year disease-free survival of 25% which des...

Descripción completa

Detalles Bibliográficos
Autores principales: Modesto, Anouchka, Tougeron, David, Tremolières, Pierre, Ronchin, Philippe, Jouve, Ariane Darut, Leignel, Delphine Argo, Vendrely, Véronique, Riou, Olivier, Martin-Babau, Jérôme, Le Sourd, Samuel, Mirabel, Xavier, Leroy, Thomas, Huguet, Florence, Montaigne, Lucile, Baumgaertner, Isabelle, Deslandres, Marion, Moyal, Elizabeth, Seva, Catherine, Selves, Janick, Otal, Philippe, Pezzella, Veronica, Guimbaud, Rosine, Filleron, Thomas, Quéro, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568784/
https://www.ncbi.nlm.nih.gov/pubmed/37828434
http://dx.doi.org/10.1186/s12885-023-11227-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568784/
https://www.ncbi.nlm.nih.gov/pubmed/37828434
http://dx.doi.org/10.1186/s12885-023-11227-0

Ejemplares similares